BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:OPN-6602 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of OPN-6602\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06433947-3434@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:OPN-6602: Phase 1 readout est. (NCT06433947)
DESCRIPTION:OPN-6602\, phase 1\, Multiple Myeloma.\nStudy: Study to Assess 
 Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refra
 ctory Multiple Myeloma\nEstimated primary completion: December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/opn-6602#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06433947
URL:https://assetmemo.bio/drug/opn-6602#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
